AUTHOR INDEX TO VOLUME 4

Atwood B, 39
Averbuch M, 199

Ballard R, 7
Bankowski Z, 83
Barnett ST, 7
Blumenthal SJ, 183
Bruppacher R, 91
Butler JP, 253

Castle W, 83
Cato A, 1
Cocchetto DM, 99, 157
Council for International Organizations of Medical Sciences ADR Working Group, 83
Cuerrier G, 155

Dahlöf C, 205
Dalton M, 39
DiCerbo PA, 235
Dimenäs E, 205
Dobbs JH, 227

Edlavitch SA, 107
Edwards M, 191

Faich GA, 83

Guess HA, 183
Guth D, 55

Hansen LG, 219
Harwood F, 7
Hilsinger R, 7

Johnson JR, 73

Kaitin KI, 235
Kaja R, 55

Lanes SF, 161, 175
Lasagna L, 25
Leong RW, 55
Lydick E, 183
Lyon G, 39

Meltzer EO, 99
Miller L, 39

Neidl M, 253
Norris DR, 263

Olofsson B, 205

Perkins JG, 39
Phillips MR, 263
Pierce LR, 71
Pollock DJ, 199
Porta M, 241

Schwemer GT, 76
Sheridan AQ, 55
Smith Rogers A, 241
Stuart JC, 253
Swinehart JM, 61

Thompson WL, 3
Tilson HH, 91, 241

Vestal R, 39

Walker AM, 161, 175
Warwick WJ, 219
Wastila LJ, 25
Weintraub M, 199
Wiklund I, 205
Wilkinson GS, 161, 175

Zawel J, 161

Journal of Clinical Research and Pharmacoepidemiology 4, 273 (1990)

© 1990 Associates of Clinical Pharmacology

Published by Elsevier Science Publishing Co., Inc.
655 Avenue of the Americas, New York, NY 10010

0889-5813/90/$3.50

SUBJECT INDEX TO VOLUME 4

ABSTRACTS
Abstracts: 6th International Conference on Pharmacoepidemiology, August 8–10, 1990, Anaheim, California, 113
ACP Spring 1990 Poster Abstracts, May 8–10, 1990, Montreal, Quebec, Canada, 147
Student Award Abstract: The Role of the Hepatic Artery in Drug Removal, 155

ADVERSE DRUG REACTIONS (ADR)
Case Report of a Patient with Acute Appendicitis and Hepatitis-A During a Clinical Trial: A Setting for Review of Adverse Event Reporting Requirements, 99
International Adverse Drug Reporting: The CIOMS Project, 83

ADVERSE DRUG REPORTS
Learning to See: Twenty Years of Renal Adverse Experience Reporting with Indocin, 183

AIDS
The History of Zidovudine (AZT), 25

ANTIHYPERTENSIVE DRUGS
An Instrument for Quantifying Subjective Symptoms Among Untreated and Treated Hypertensives: Development and Documentation, 205

ASSESSMENTS
Quality of Life: II. Oncology: Regulatory/Scientific Aspects and the Drug Approval Process, 39

AUDIOVISUAL
Using Instructive Videotapes to Increase Patient Comprehension of Informed Consent, 263

AZATHIOPRINE
Differences in Complication Rates Between Cyclosporine and Other Immunosuppressive Agents: A Quantitative Review, 175

AZT
The History of Zidovudine (AZT), 25

CANDA
Computer-Assisted New Drug Applications (CANDAs): A Review, 227

CHEMOTHERAPY
Oncology Updated, 4

CHRONIC STABLE ANGINA
Experimental Designs for Clinical Trials in Chronic Stable Angina, 76

CILIA BEAT FREQUENCY
Theophylline and Human Nasal Ciliary Beat Frequency: Research Report, 219

CIOMS
International Adverse Drug Reporting: The CIOMS Project, 83

CLINICAL DATA SECTION OF REGULATORY DOCUMENTS
Preparation of the Clinical Section of Regulatory Documents: A Case Study, 55

CLINICAL DEVELOPMENT
The Clinical Development Plan: A Guide for Writers and Readers, 191

CLINICAL MONITORS
A Comprehensive Interactive Training Program for Clinical Monitors, 253

CLINICAL PHARMACOLOGY
Clinical Research Practices for the 1990s: Results of a Survey Conducted for the Associates of Clinical Pharmacology, 7

CLINICAL RESEARCH
Clinical Research Practices for the 1990s: Results of a Survey Conducted for the Associates of Clinical Pharmacology, 7
Survival on the Battlefield of Clinical Research, 157
Use of a Study Tracking Computer Program in a Clinical Research Center, 61

CLINICAL TRIALS
Case Report of a Patient with Acute Appendicitis and Hepatitis-A During a Clinical Trial: A Setting for Review of

Journal of Clinical Research and Pharmacoepidemiology 4, 275–278 (1990)

© 1990 Associates of Clinical Pharmacology

Published by Elsevier Science Publishing Co., Inc.
655 Avenue of the Americas, New York, NY 10010

0889-5813/90/$3.50

Adverse Event Reporting Requirements, 99
Compliance Assessment in Clinical Trials: The MEMS Device, 199
Experimental Designs for Clinical Trials in Chronic Stable Angina, 76

COMPUTERS
Computer-Assisted New Drug Applications (CANDAs): A Review, 227
Use of a Study Tracking Computer Program in a Clinical Research Center, 61

CONSENSUS
Guidelines for Decision Making in Postmarketing Surveillance of Drugs, 241

COST OF DRUGS
The History of Zidovudine (AZT), 25

CYCLOSPORINE
Differences in Complication Rates Between Cyclosporine and Other Immunosuppressive Agents: A Quantitative Review, 175
Treatment Efficacy of Cyclosporine in Renal Transplantation: A Quantitative Review of All Randomized Clinical Trials, 161

DECISION MAKING
Guidelines for Decision Making in Postmarketing Surveillance of Drugs, 241

DRUG APPROVAL PROCESS
FDA Approval Reqirements for Lipid-Altering Agents, 71
Recent Trends in the United States Drug Approval Process, 235
Study Design and FDA Approval Requirements for Cancer Drugs, 73

DRUG DEVELOPMENT
The Clinical Development Plan: A Guide for Writers and Readers, 191
The History of Zidovudine (AZT), 25

DRUG SAFETY
Guidelines for Decision Making in Postmarketing Surveillance of Drugs, 241

EPIDEMIOLOGY
A Working Group on Epidemiology in the Pharmaceutical Industry (EPI): A New Force for the Field, 91

EXPERIMENTAL THERAPEUTICS
"Drug Development—The Next Decade," 3

FDA APPROVAL REQUIREMENTS
FDA Approval Reqirements for Lipid-Altering Agents, 71
Recent Trends in the United States Drug Approval Process, 235
Study Design and FDA Approval Requirements for Cancer Drugs, 73

GALLBLADDER STONES
Gallbladder Stones: New Causes and New Non-Surgical Treatments, 5

GUIDELINES
Guidelines for Decision Making in Postmarketing Surveillance of Drugs, 241

HEPATIC ARTERY IN DRUG REMOVAL
The Role of the Hepatic Artery in Drug Removal, 155

HYPERTENSION
Differences in Complication Rates Between Cyclosporine and Other Immunosuppressive Agents: A Quantitative Review, 175

INDOMETHACIN
Learning to See: Twenty Years of Renal Adverse Experience Reporting with Indocin, 183

INFECTION
Differences in Complication Rates Between Cyclosporine and Other Immunosuppressive Agents: A Quantitative Review, 175

INFORMED CONSENT
Using Instructive Vidoetapes to Increase Patient Comprehension of Informed Consent, 263

INTERACTIVE TRAINING PROGRAM FOR CLINICAL MONITORS
A Comprehensive Interactive Training Program for Clinical Monitors, 253

INTERNATIONAL PHARMACEUTICAL REGULATION
International Adverse Drug Reporting: The CIOMS Project, 83

LIPID-ALTERING AGENTS
FDA Approval Requirements for Lipid-Altering Agents, 71

MEDICATION EVENT MONITORING SYSTEM (MEMS)
Compliance Assessment in Clinical Trials: The MEMS Device, 199

NDA REVIEW
Computer-Assisted New Drug Applications (CANDAs): A Review, 227

NEPHROTOXICITY
Differences in Complication Rates Between Cyclosporine and Other Immunosuppressive Agents: A Quantitative Review, 175

NEW CHEMICAL ENTITY
Recent Trends in the United States Drug Approval Process, 235

ONCOLOGY
Quality of Life: II. Oncology: Regulatory/Scientific Aspects and the Drug Approval Process, 39
Study Design and FDA Approval Requirements for Cancer Drugs, 73

PATIENT EDUCATION
Using Instructive Videotapes to Increase Patient Comprehension of Informed Consent, 263

PHARMACEUTICAL INDUSTRY
A Working Group on Epidemiology in the Pharmaceutical Industry (EPI): A New Force for the Field, 91

PHARMACOEPIDEMIOLOGY
Abstracts: 6th International Conference on Pharmacoepidemiology, August 8–10, 1990, Anaheim, California, 113
Pharmacoepidemiology: A Banner Year, 107

PMA MEETING
Meeting Presentations of November 1, 1988 Meeting, 71

POSTMARKETING SURVEILLANCE
Guidelines for Decision Making in Postmarketing Surveillance of Drugs, 241

PROGRAMS
Use of a Study Tracking Computer Program in a Clinical Research Center, 61

PROPORTIONATE ANALYSIS
Learning to See: Twenty Years of Renal Adverse Experience Reporting with Indocin, 183

PROSTAGLANDIN
Learning to See: Twenty Years of Renal Adverse Experience Reporting with Indocin, 183

QUALITY OF LIFE
An Instrument for Quantifying Subjective Symptoms Among Untreated and Treated Hypertensives: Development and Documentation, 205
Quality of Life: II. Oncology: Regulatory/Scientific Aspects and the Drug Approval Process, 39

RANDOM CLINICAL TRIALS
Treatment Efficacy of Cyclosporine in Renal Transplantation: A Quantitative Review of All Randomized Clinical Trials, 161

RECOMMENDATIONS FOR REGULATORY DOCUMENT PREPARATION
Preparation of the Clinical Section of Regulatory Documents: A Case Study, 55

REGULATORY DOCUMENTS
Preparation of the Clinical Section of Regulatory Documents: A Case Study, 55

REGULATORY/SCIENTIFIC
Quality of Life: II. Oncology: Regulatory/Scientific Aspects and the Drug Approval Process, 39

RENAL TRANSPLANTS
Differences in Complication Rates Between Cyclosporine and Other Immunosuppressive Agents: A Quantitative Review, 175
Treatment Efficacy of Cyclosporine in Renal Transplantation: A Quantitative Review of All Randomized Clinical Trials, 161

RISK ASSESSMENT OF DRUGS-ANALYSIS AND RESPONSE (RADAR)
A Working Group on Epidemiology in the Pharmaceutical Industry (EPI): A New Force for the Field, 91

SIDE EFFECTS
An Instrument for Quantifying Subjective Symptoms Among Untreated and

Treated Hypertensives: Development and Documentation, 205

SUBJECTIVE SYMPTOMS
An Instrument for Quantifying Subjective Symptoms Among Untreated and Treated Hypertensives: Development and Documentation, 205

THEOPHYLLINE
Theophylline and Human Nasal Ciliary Beat Frequency: Research Report, 219

TRAINING PROGRAM FOR CLINICAL MONITORS
A Comprehensive Interactive Training Program for Clinical Monitors, 253

VIDEOTAPE
Using Instructive Videotapes to Increase Patient Comprehension of Informed Consent, 263

ZIDOVUDINE
The History of Zidovudine (AZT), 25